Jury Rejects Doctor's Claim Over Genentech Drug

Law360, New York (November 9, 2006, 12:00 AM EST) -- A Pennsylvania jury decided Wednesday that biotech company Genentech Inc. does not have to pay an ophthalmologist for research used in the development of its drug Lucentis.

Kourosh Dastgheib filed the claim in March 2003 when Lucentis, a drug used to treat the degenerative eye disease wet age-related macular degeneration, was in clinical trials.

Dastgheib claimed he made an agreement with San Francisco-based Genentech in which he would provide macular degeneration research in return for a share of the drug’s profits.

In a recent filing with...
To view the full article, register now.